AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
OmniAb, Inc.
Video analysis: OABI
All videosNo video analysis for this stock yet. Request one from our team.
News: OABI
OmniAb to Host Investor & Analyst Day on October 6, 2026
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #Antibody--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reiterates details of its upcoming Investor & Analyst Day, to be held on October 6, 2026, in Emeryville, CA. The event will feature presentations from OmniAb's executive leadership team, including corporate updates, select partner programs, the xPloration® platform, technology innovations and a Q&A sessi.
OmniAb to Participate in Upcoming Investor Conferences
OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced m
OmniAb to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced management's participation in the following upcoming investor conferences: Nasdaq/LD Micro Summit Series Date: Wednesday, September 9, 2026 H.C. Wainwright 28th Annual Global Investment Conference Date: Tuesday, September 15, 2026 The Nasdaq/LD Micro Summit will take place at the Nasdaq Headquarters in.
OmniAb: Lilly-Style Partners Are Paying Attention To This Early-Stage Biotech
OmniAb is transitioning from early-stage biotech to a scalable platform, driven by milestone-rich partnerships like the recent Eli Lilly deal. OABI's 110 partners and 425 programs are generating higher, more predictable milestone revenues, with $340M in clinical-stage milestone potential and a $3B+ total milestone pool. The Lilly collaboration validates OABI's technology, offers high-margin, capital-light economics, and has directly improved 2026 cash guidance to $49–$53M.
OmniAb Raises 2026 Financial Guidance
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today raised its 2026 cash and cash equivalents financial guidance following recent technology licensing activity. “Recent business development and licensing activity has enabled us to again raise our 2026 financial guidance and significantly increase our cash outlook,” stated Matt Foehr, Chief Executive Officer of Om.
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced a global collaboration and license agreement with Eli Lilly and Company (Lilly) for a new ion channel program. The collaboration leverages OmniAb's technology platform and expertise in ion channel discovery and screening. “We are pleased to enter into this important new relationship with Lilly,” said M.
OmniAb, Inc. (OABI) Q2 2026 Earnings Call Transcript
OmniAb, Inc. (OABI) Q2 2026 Earnings Call Transcript
OmniAb Q2 Earnings Call Highlights
OmniAb NASDAQ: OABI reported higher second-quarter revenue and a narrower net loss as milestone payments from partner programs increased, while the company raised its full-year 2026 revenue and year-end cash outlook.
